These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 19765886)

  • 21. Re: Matthias May, Sabine Brookman-Amissah, Jan Roigas, et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol 2010;57:850-8.
    Yorukoglu K; Tuna B; Kirkali Z
    Eur Urol; 2010 Jul; 58(1):e7; author reply e8. PubMed ID: 20382470
    [No Abstract]   [Full Text] [Related]  

  • 22. Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer.
    Kwak C; Ku JH; Park JY; Lee E; Lee SE; Lee C
    J Urol; 2004 Jan; 171(1):149-52. PubMed ID: 14665864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. E-cadherin mRNA expression analysis in evaluating the natural history of urothelial bladder cell carcinoma: results from a long-term follow-up study.
    Cai T; Piazzini M; Nesi G; Taddei I; Sardi I; Detti B; Mondaini N; Dal Canto M; Bartoletti R
    Oncol Rep; 2007 Apr; 17(4):925-30. PubMed ID: 17342338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
    Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
    J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology.
    Alsheikh A; Mohamedali Z; Jones E; Masterson J; Gilks CB
    Mod Pathol; 2001 Apr; 14(4):267-72. PubMed ID: 11301341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The prognostic factors in T1 superficial bladder carcinoma. Our experience].
    Moyano Calvo JL; Romero Díaz A; Ortíz Gamiz A; Sánchez Sánchez E; Blanco Palenciano E; Arribas Rodríguez JM; Castiñeiras Fernández J
    Arch Esp Urol; 1999 Jun; 52(5):465-70. PubMed ID: 10427884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically.
    Saito K; Kawakami S; Fujii Y; Sakura M; Masuda H; Kihara K
    J Urol; 2007 Dec; 178(6):2291-6; discussion 2296. PubMed ID: 17936818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. External beam radiation therapy followed by interstitial radiotherapy with iridium-192 for solitary bladder tumours: results of 111 treated patients.
    van Onna IE; Oddens JR; Kok ET; van Moorselaar RJ; Bosch JL; Battermann JJ
    Eur Urol; 2009 Jul; 56(1):113-21. PubMed ID: 18722048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
    Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
    J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma.
    Tsui KH; Cheng AJ; Chang Pe; Pan TL; Yung BY
    Urology; 2004 Oct; 64(4):839-44. PubMed ID: 15491744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer.
    Sonpavde G; Khan MM; Lerner SP; Svatek RS; Novara G; Karakiewicz PI; Skinner E; Tilki D; Kassouf W; Fradet Y; Dinney CP; Fritsche HM; Izawa JI; Bastian PJ; Ficarra V; Schoenberg M; Sagalowsky AI; Lotan Y; Shariat SF
    J Urol; 2011 Feb; 185(2):456-61. PubMed ID: 21167527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome.
    Tilki D; Reich O; Karakiewicz PI; Novara G; Kassouf W; Ergün S; Fradet Y; Ficarra V; Sonpavde G; Stief CG; Skinner E; Svatek RS; Lotan Y; Sagalowsky AI; Shariat SF
    Eur Urol; 2010 Jul; 58(1):112-7. PubMed ID: 20097469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Behavior of urothelial carcinoma with respect to anatomical location.
    Catto JW; Yates DR; Rehman I; Azzouzi AR; Patterson J; Sibony M; Cussenot O; Hamdy FC
    J Urol; 2007 May; 177(5):1715-20. PubMed ID: 17437794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin.
    Palou J; Algaba F; Vera I; Rodriguez O; Villavicencio H; Sanchez-Carbayo M
    Eur Urol; 2009 Nov; 56(5):829-36. PubMed ID: 18926620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Qualitative and quantitative histopathology in transitional cell carcinomas of the urinary bladder. An international investigation of intra- and interobserver reproducibility.
    Sørensen FB; Sasaki M; Fukuzawa S; Yamabe H; Olsen S; Yoshida O
    Lab Invest; 1994 Feb; 70(2):242-54. PubMed ID: 8139265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Superficial grade G2 tumors of the bladder: recurrence, progression, prognosis].
    Sebe P; Lebret T; Molinie V; Herve JM; Yonneau L; Lugagne PM; Saporta F; Orsoni JL; Butreau M; Botto H
    Prog Urol; 2003 Sep; 13(4):608-12. PubMed ID: 14650291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reproducibility and Prognostic Performance of the 1973 and 2004 World Health Organization Classifications for Grade in Non-muscle-invasive Bladder Cancer: A Multicenter Study in 328 Bladder Tumors.
    Bosschieter J; Hentschel A; Savci-Heijink CD; Patrick van der Voorn J; Rozendaal L; Vis AN; van Rhijn BWG; Lissenberg-Witte BI; Fransen van de Putte EE; van Moorselaar RJA; Nieuwenhuijzen JA
    Clin Genitourin Cancer; 2018 Oct; 16(5):e985-e992. PubMed ID: 29884516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chromosomal high-polysomies predict tumour progression in T1 transitional cell carcinoma of the bladder.
    Ribal MJ; Alcaraz A; Mengual L; Carrio A; Lopez-Guillermo A; Mallofré C; Palou J; Gelabert A; Villavicencio H
    Eur Urol; 2004 May; 45(5):593-9. PubMed ID: 15082201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.